Pristane-Induced Plasmacytoma Model Service

The Pristane-Induced Plasmacytoma Model Service offers a rigorously characterized in vivo platform in which immunoglobulin-secreting plasma cell tumors are generated in genetically susceptible BALB/c mice, faithfully recapitulating the inflammation-driven pathogenesis of human multiple myeloma and related B-cell neoplasms. Alfa Cytology supports every phase of this model — from protocol design, pristane administration scheduling and longitudinal tumor surveillance to terminal serological, histopathological and molecular characterization — enabling your team to generate robust, decision-ready preclinical datasets with confidence.

Overview of Pristane-Induced Plasmacytoma Model

The pristane-induced plasmacytoma model is a chemically induced, inflammation-driven system for studying plasma cell malignancy. First described in 1969, the model is based on the intraperitoneal administration of pristane (2,6,10,14-tetramethylpentadecane), a branched isoprenoid alkane that is poorly metabolized and persists locally within the peritoneal cavity. In susceptible BALB/c substrains, this treatment provokes the development of monoclonal plasma cell tumors that arise within oil-induced granulomatous tissue, typically accompanied by ascites and by the secretion of a monoclonal immunoglobulin — an M-protein analogous to the disease-defining marker of human multiple myeloma.

Fig 1. PCT incidence curves in wild-type, heterozygous and hs3b-4 knockout mice post-pristane, H&E of plasmacytoma cells with clock-face nuclei in oil granuloma, and Igh 3′RR FISH probe maps of WT versus deleted chromosome 12. (Kovalchuk, Alexander L., et al., 2018)

Mechanistically, the model is governed by a sustained inflammatory microenvironment: chronic granuloma formation provides stromal support and abundant interleukin-6 (IL-6), which drives the survival and proliferation of transformed plasma cells. Tumorigenesis is consistently associated with chromosomal translocations, most characteristically t(12;15) and t(6;15), that juxtapose the c-myc oncogene with immunoglobulin heavy-chain regulatory elements and lock it into continuous expression. Because it reproduces both the molecular lesions and the microenvironmental dependencies of human disease, the pristane model remains a cornerstone for investigating myeloma initiation and progression in vivo, dissecting tumor–stroma interactions, and benchmarking candidate therapeutics — from IL-6 pathway modulators to bisphosphonates — long before any clinical consideration.

Principles of Pristane-Induced Plasmacytoma Model Construction

Pristane is not a genotoxic carcinogen; rather, its tumor-promoting activity stems from the durable irritant and inflammatory response it elicits in the peritoneal cavity. The retained oil is encapsulated within lipogranulomas rich in macrophages, T lymphocytes and reactive stromal elements, which together create a cytokine-rich niche dominated by IL-6. Within this niche, repeatedly stimulated B lymphocytes undergo plasma cell differentiation, and rare pre-neoplastic plasma cell foci — detectable within weeks of injection — progressively expand under selective pressure. The critical transforming event is a reciprocal chromosomal translocation placing c-myc under the transcriptional control of Igh enhancers, after which a single clone expands to overgrow the granuloma and seed ascitic tumor. Susceptibility is strongly strain-dependent (multigenic), and tumor incidence is further shaped by environmental antigenic stimulation, since mice maintained under strict specific pathogen-free conditions are largely refractory.

Our Services

Alfa Cytology provides a comprehensive, quality-controlled Pristane-Induced Plasmacytoma Model Service tailored to preclinical research programs: our experienced team handles strain selection, pristane dosing schedules, animal health surveillance, serial M-protein quantification, and full endpoint workups — including histopathology, immunophenotyping and molecular confirmation of Igh–c-myc rearrangements — so that every study concludes with interpretable, publication-grade results delivered on time.

Workflow of Pristane-Induced Plasmacytoma Model Construction

Construction of the pristane-induced plasmacytoma model is a long-term, multistage process spanning several months from induction to confirmed tumor readout. The workflow below outlines each phase of model development and the analytical checkpoints applied along the way.

1. Study design and model planning: The experimental plan is defined, covering mouse strain and sex selection, group size, randomization and blinding strategy, dosing regimen (single versus repeated pristane injections), and pre-specified endpoints aligned with the research objective.
2. Animal sourcing and acclimatization: Genetically susceptible BALB/c mice are obtained from qualified vendors and acclimatized under husbandry conditions that preserve model permissiveness, with baseline health status and body weights recorded.
3. Pristane administration: Pristane is delivered by intraperitoneal injection (classically 0.5 mL per injection, given once or repeated at two-month intervals), with post-injection monitoring for injection-site reactions and general well-being.
4. Longitudinal health and tumor surveillance: Mice are monitored on a scheduled basis for body weight change, abdominal distension suggestive of ascites, palpable peritoneal masses, and overall clinical condition, with humane endpoints strictly enforced.
5. Serial M-protein detection: Periodic serum sampling is analyzed by protein electrophoresis and/or antigen-specific assays to detect and quantify the emerging monoclonal immunoglobulin, providing an early quantitative marker of plasmacytoma development.
6. Tumor confirmation and sample collection: Upon endpoint, peritoneal lavage and ascitic fluid are collected, tumor-involved granulomatous tissue is excised, and specimens are processed for downstream analyses, with in vitro cultures established where required.
7. Histopathology and immunophenotyping: Tissues are examined by H&E staining and plasma cell markers (e.g., CD138 and immunoglobulin light-chain staining) to confirm diagnosis, assess clonality, and characterize tumor architecture.
8. Molecular analysis and data reporting: Molecular confirmation of characteristic Igh–c-myc rearrangements is performed where specified, and cumulative datasets — tumor incidence, latency distributions, M-protein kinetics and survival curves — are compiled into a final study report.

Fig 2. Pristane-Induced Plasmacytoma Model Construction Workflow.

Case Study-Pristane-Induced Plasmacytoma Model Development

Alfa Cytology has applied the pristane-induced plasmacytoma model across a range of preclinical research programs, supporting clients in evaluating candidate agents directed at plasma cell survival, IL-6 signaling and the tumor microenvironment. Representative engagements have encompassed the full model lifecycle — pristane induction, scheduled dosing, serial serum M-protein monitoring, and terminal histopathological and molecular confirmation of tumor clonality — generating incidence, latency and treatment-response datasets suitable for internal decision-making and further development planning. Detailed case materials and study data are available upon request.

Why Choose Alfa Cytology?

Selecting the right CRO partner determines whether a long-latency, technically demanding model yields publishable, decision-grade data. Alfa Cytology combines specialized expertise in inflammation-driven B-cell tumor models with disciplined, quality-controlled operations to keep every study on track from induction to final report.

• Deep, hands-on experience with the pristane model and its strain, environment and husbandry dependencies.
• Standardized dosing regimens with documented tumor incidence and latency performance.
• Integrated serological (M-protein), histopathological, immunophenotypic and molecular endpoints under one roof.
• Flexible therapeutic-intervention designs, with treatment initiated at induction or after confirmed tumor onset.
• Dedicated preclinical-only focus — no clinical services — ensuring undivided attention to your research-stage program.
• Responsive study management with scheduled interim updates and on-time final data delivery.

Contact Us

Ready to advance your multiple myeloma research with a proven in vivo plasmacytoma platform? Contact us today to discuss your study objectives, and our scientific team will propose a customized Pristane-Induced Plasmacytoma Model Service plan built around your timeline and endpoints. Reach out to Alfa Cytology now to get started.

For research use only. Not intended for any clinical use.